2014 Q2 Form 10-Q Financial Statement
#000119312514194791 Filed on May 12, 2014
Income Statement
Concept | 2014 Q2 | 2014 Q1 | 2013 Q1 |
---|---|---|---|
Revenue | $0.00 | $0.00 | |
YoY Change | |||
Cost Of Revenue | |||
YoY Change | |||
Gross Profit | |||
YoY Change | |||
Gross Profit Margin | |||
Selling, General & Admin | $3.900M | $3.530M | $2.270M |
YoY Change | 71.81% | 55.51% | 77.34% |
% of Gross Profit | |||
Research & Development | $35.00M | $16.29M | $9.532M |
YoY Change | 235.26% | 70.94% | -9.8% |
% of Gross Profit | |||
Depreciation & Amortization | $150.0K | $130.0K | $90.00K |
YoY Change | 50.0% | 44.44% | 80.0% |
% of Gross Profit | |||
Operating Expenses | $38.91M | $19.82M | $11.81M |
YoY Change | 206.17% | 67.87% | -0.39% |
Operating Profit | -$38.91M | -$19.82M | -$11.81M |
YoY Change | 206.17% | 67.87% | -0.39% |
Interest Expense | $70.00K | $50.00K | $20.00K |
YoY Change | -30.0% | 150.0% | -33.33% |
% of Operating Profit | |||
Other Income/Expense, Net | $61.00K | $25.00K | $26.00K |
YoY Change | 7.02% | -3.85% | 0.0% |
Pretax Income | -$38.84M | -$19.79M | -$11.78M |
YoY Change | 207.04% | 68.0% | -0.42% |
Income Tax | $0.00 | $0.00 | $0.00 |
% Of Pretax Income | |||
Net Earnings | -$38.84M | -$19.79M | -$11.78M |
YoY Change | 207.07% | 68.03% | -0.39% |
Net Earnings / Revenue | |||
Basic Earnings Per Share | |||
Diluted Earnings Per Share | -$1.290M | -$669.3K | -$410.7K |
COMMON SHARES | |||
Basic Shares Outstanding | 30.12M shares | 30.12M shares | 28.68M shares |
Diluted Shares Outstanding |
Balance Sheet
Concept | 2014 Q2 | 2014 Q1 | 2013 Q1 |
---|---|---|---|
SHORT-TERM ASSETS | |||
Cash & Short-Term Investments | $178.4M | $196.1M | $118.7M |
YoY Change | 65.95% | 65.21% | 136.45% |
Cash & Equivalents | $55.40M | $163.4M | $91.65M |
Short-Term Investments | $123.0M | $32.70M | $27.10M |
Other Short-Term Assets | $3.500M | $2.300M | $2.100M |
YoY Change | 218.18% | 9.52% | 320.0% |
Inventory | |||
Prepaid Expenses | |||
Receivables | $1.800M | $13.30M | $17.30M |
Other Receivables | $1.760M | $13.30M | $9.800M |
Total Short-Term Assets | $183.6M | $211.7M | $138.2M |
YoY Change | 48.74% | 53.16% | 172.53% |
LONG-TERM ASSETS | |||
Property, Plant & Equipment | $1.900M | $1.769M | $1.572M |
YoY Change | 15.29% | 12.53% | 48.72% |
Goodwill | |||
YoY Change | |||
Intangibles | |||
YoY Change | |||
Long-Term Investments | |||
YoY Change | |||
Other Assets | $10.50M | $6.800M | $1.200M |
YoY Change | 262.07% | 466.67% | 9.09% |
Total Long-Term Assets | $12.50M | $8.590M | $2.821M |
YoY Change | 174.91% | 204.5% | 33.64% |
TOTAL ASSETS | |||
Total Short-Term Assets | $183.6M | $211.7M | $138.2M |
Total Long-Term Assets | $12.50M | $8.590M | $2.821M |
Total Assets | $196.1M | $220.3M | $141.0M |
YoY Change | 53.22% | 56.18% | 166.98% |
SHORT-TERM LIABILITIES | |||
YoY Change | |||
Accounts Payable | $18.80M | $15.19M | $6.887M |
YoY Change | 146.59% | 120.59% | 1115.32% |
Accrued Expenses | $9.100M | $5.051M | $14.74M |
YoY Change | -25.4% | -65.74% | 65.34% |
Deferred Revenue | |||
YoY Change | |||
Short-Term Debt | $0.00 | $0.00 | $0.00 |
YoY Change | |||
Long-Term Debt Due | |||
YoY Change | |||
Total Short-Term Liabilities | $27.90M | $20.24M | $21.63M |
YoY Change | 40.75% | -6.41% | 128.09% |
LONG-TERM LIABILITIES | |||
Long-Term Debt | $0.00 | $0.00 | $0.00 |
YoY Change | |||
Other Long-Term Liabilities | $1.100M | $1.200M | $1.100M |
YoY Change | 0.0% | 9.09% | 57.14% |
Total Long-Term Liabilities | $1.100M | $1.200M | $1.100M |
YoY Change | 0.0% | 9.09% | 57.14% |
TOTAL LIABILITIES | |||
Total Short-Term Liabilities | $27.90M | $20.24M | $21.63M |
Total Long-Term Liabilities | $1.100M | $1.200M | $1.100M |
Total Liabilities | $29.00M | $21.47M | $22.74M |
YoY Change | 38.37% | -5.61% | 122.38% |
SHAREHOLDERS EQUITY | |||
Retained Earnings | |||
YoY Change | |||
Common Stock | $357.8M | $214.7M | |
YoY Change | 66.69% | 232.0% | |
Preferred Stock | |||
YoY Change | |||
Treasury Stock (at cost) | |||
YoY Change | |||
Treasury Stock Shares | |||
Shareholders Equity | $167.0M | $198.8M | $118.3M |
YoY Change | |||
Total Liabilities & Shareholders Equity | $196.1M | $220.3M | $141.0M |
YoY Change | 53.21% | 56.18% | 166.98% |
Cashflow Statement
Concept | 2014 Q2 | 2014 Q1 | 2013 Q1 |
---|---|---|---|
OPERATING ACTIVITIES | |||
Net Income | -$38.84M | -$19.79M | -$11.78M |
YoY Change | 207.07% | 68.03% | -0.39% |
Depreciation, Depletion And Amortization | $150.0K | $130.0K | $90.00K |
YoY Change | 50.0% | 44.44% | 80.0% |
Cash From Operating Activities | -$17.37M | -$17.05M | -$18.48M |
YoY Change | 57.91% | -7.76% | 563.59% |
INVESTING ACTIVITIES | |||
Capital Expenditures | -$320.0K | -$220.0K | -$180.0K |
YoY Change | 77.78% | 22.22% | -196.17% |
Acquisitions | |||
YoY Change | |||
Other Investing Activities | -$90.33M | $8.160M | -$27.10M |
YoY Change | 361.1% | -130.11% | |
Cash From Investing Activities | -$90.65M | $7.940M | -$27.28M |
YoY Change | 358.52% | -129.11% | 6333.73% |
FINANCING ACTIVITIES | |||
Cash Dividend Paid | |||
YoY Change | |||
Common Stock Issuance & Retirement, Net | $129.4M | ||
YoY Change | |||
Debt Paid & Issued, Net | |||
YoY Change | |||
Cash From Financing Activities | 0.000 | 129.4M | 0.000 |
YoY Change | |||
NET CHANGE | |||
Cash From Operating Activities | -17.37M | -17.05M | -18.48M |
Cash From Investing Activities | -90.65M | 7.940M | -27.28M |
Cash From Financing Activities | 0.000 | 129.4M | 0.000 |
Net Change In Cash | -108.0M | -17.05M | -45.76M |
YoY Change | 882.0% | -62.75% | 1325.99% |
FREE CASH FLOW | |||
Cash From Operating Activities | -$17.37M | -$17.05M | -$18.48M |
Capital Expenditures | -$320.0K | -$220.0K | -$180.0K |
Free Cash Flow | -$17.05M | -$16.83M | -$18.30M |
YoY Change | 57.58% | -8.05% | 515.75% |
Facts In Submission
Frame | Concept Type | Concept / XBRL Key | Value | Unit |
---|---|---|---|---|
CY2014Q2 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
30117819 | shares |
CY2011Q3 | pbyi |
Merger Stock Conversion Ratio
MergerStockConversionRatio
|
1.00 | pure |
CY2013Q1 | us-gaap |
Other Receivables Net Current
OtherReceivablesNetCurrent
|
9800000 | |
CY2013Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
91648000 | |
CY2014Q1 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
30117819 | shares |
CY2014Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
1011732 | shares |
CY2014Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
35.52 | |
CY2014Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
3059849 | shares |
CY2014Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
|
2048117 | shares |
CY2014Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
|
9.46 | |
CY2014Q1 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | shares |
CY2014Q1 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
CY2014Q1 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
30117819 | shares |
CY2014Q1 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
20243000 | |
CY2014Q1 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
-6000 | |
CY2014Q1 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
1717000 | |
CY2014Q1 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
832000 | |
CY2014Q1 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
27000 | |
CY2014Q1 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
15192000 | |
CY2014Q1 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
252000 | |
CY2014Q1 | us-gaap |
Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
|
1223000 | |
CY2014Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
198787000 | |
CY2014Q1 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
357835000 | |
CY2014Q1 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
5051000 | |
CY2014Q1 | us-gaap |
Liabilities
Liabilities
|
21466000 | |
CY2014Q1 | us-gaap |
Common Stock Value
CommonStockValue
|
3000 | |
CY2014Q1 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
220253000 | |
CY2014Q1 | us-gaap |
Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
|
1214000 | |
CY2014Q1 | us-gaap |
Other Receivables Net Current
OtherReceivablesNetCurrent
|
13296000 | |
CY2014Q1 | us-gaap |
Leasehold Improvements Gross
LeaseholdImprovementsGross
|
1020000 | |
CY2014Q1 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
2601000 | |
CY2014Q1 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
1769000 | |
CY2014Q1 | us-gaap |
Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
|
5607000 | |
CY2014Q1 | us-gaap |
Assets
Assets
|
220253000 | |
CY2014Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
163380000 | |
CY2014Q1 | us-gaap |
Furniture And Fixtures Gross
FurnitureAndFixturesGross
|
534000 | |
CY2014Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
|
95791000 | |
CY2014Q1 | us-gaap |
Cash Uninsured Amount
CashUninsuredAmount
|
164600000 | |
CY2014Q1 | us-gaap |
Development Stage Enterprise Deficit Accumulated During Development Stage
DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage
|
159045000 | |
CY2014Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
214356000 | |
CY2014Q1 | us-gaap |
Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
|
7860000 | |
CY2014Q1 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
2253000 | |
CY2014Q1 | us-gaap |
Marketable Securities Current
MarketableSecuritiesCurrent
|
32734000 | |
CY2014Q1 | us-gaap |
Assets Current
AssetsCurrent
|
211663000 | |
CY2014Q1 | pbyi |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term3
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3
|
P8Y9M18D | |
CY2014Q1 | pbyi |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Intrinsic Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedIntrinsicValue
|
118565000 | |
CY2014Q1 | pbyi |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Exercise Price
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageExercisePrice
|
48.39 | |
CY2014Q1 | pbyi |
Accrued Development Costs
AccruedDevelopmentCosts
|
1784000 | |
CY2014Q1 | pbyi |
Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
|
1271000 | |
CY2011Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
54372000 | |
CY2012Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
8.93 | |
CY2012Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
1906334 | shares |
CY2012Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
128909000 | |
CY2012Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
137408000 | |
CY2013Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
28991289 | shares |
CY2013Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
23.31 | |
CY2013Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
2604224 | shares |
CY2013Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | shares |
CY2013Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
CY2013Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
28991289 | shares |
CY2013Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
19271000 | |
CY2013Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
3000 | |
CY2013Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
1066000 | |
CY2013Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
699000 | |
CY2013Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
259000 | |
CY2013Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
10692000 | |
CY2013Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
84000 | |
CY2013Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
8579000 | |
CY2013Q4 | us-gaap |
Liabilities
Liabilities
|
20387000 | |
CY2013Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
83987000 | |
CY2013Q4 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
223232000 | |
CY2013Q4 | us-gaap |
Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
|
1116000 | |
CY2013Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
3000 | |
CY2013Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
104374000 | |
CY2013Q4 | us-gaap |
Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
|
1214000 | |
CY2013Q4 | us-gaap |
Other Receivables Net Current
OtherReceivablesNetCurrent
|
9813000 | |
CY2013Q4 | us-gaap |
Leasehold Improvements Gross
LeaseholdImprovementsGross
|
914000 | |
CY2013Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
2383000 | |
CY2013Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
1684000 | |
CY2013Q4 | us-gaap |
Prepaid Expense And Other Assets Noncurrent
PrepaidExpenseAndOtherAssetsNoncurrent
|
5080000 | |
CY2013Q4 | us-gaap |
Assets
Assets
|
104374000 | |
CY2013Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
43044000 | |
CY2013Q4 | us-gaap |
Furniture And Fixtures Gross
FurnitureAndFixturesGross
|
513000 | |
CY2013Q4 | us-gaap |
Development Stage Enterprise Deficit Accumulated During Development Stage
DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage
|
139251000 | |
CY2013Q4 | us-gaap |
Prepaid Expense And Other Assets
PrepaidExpenseAndOtherAssets
|
7715000 | |
CY2013Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
2635000 | |
CY2013Q4 | us-gaap |
Marketable Securities Current
MarketableSecuritiesCurrent
|
40904000 | |
CY2013Q4 | us-gaap |
Assets Current
AssetsCurrent
|
96396000 | |
CY2013Q4 | pbyi |
Accrued Development Costs
AccruedDevelopmentCosts
|
4801000 | |
CY2013Q4 | pbyi |
Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
|
2369000 | |
us-gaap |
Equity Issuance Per Share Amount
EquityIssuancePerShareAmount
|
0.0001 | ||
us-gaap |
Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
|
7000 | ||
us-gaap |
Stock Issued During Period Value Issued For Cash
StockIssuedDuringPeriodValueIssuedForCash
|
|||
us-gaap |
Net Income Loss
NetIncomeLoss
|
-7000 | ||
us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-117938000 | ||
us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-117938000 | ||
us-gaap |
Payments For Capital Improvements
PaymentsForCapitalImprovements
|
918000 | ||
us-gaap |
Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
|
1214000 | ||
us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
-6000 | ||
us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
320000 | ||
us-gaap |
Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
|
13296000 | ||
us-gaap |
Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
|
49347000 | ||
us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-159045000 | ||
us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-99000 | ||
us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-159051000 | ||
us-gaap |
Other Noncash Income Expense
OtherNoncashIncomeExpense
|
-903000 | ||
us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-159266000 | ||
us-gaap |
Payments For Proceeds From Productive Assets
PaymentsForProceedsFromProductiveAssets
|
1683000 | ||
us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
221000 | ||
us-gaap |
Net Income Loss
NetIncomeLoss
|
-159045000 | ||
us-gaap |
Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
|
150000 | ||
us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
317873000 | ||
us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
47464000 | ||
us-gaap |
Share Based Compensation
ShareBasedCompensation
|
14157000 | ||
us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-36555000 | ||
us-gaap |
Operating Expenses
OperatingExpenses
|
159266000 | ||
us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
832000 | ||
us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
163380000 | ||
us-gaap |
Proceeds From Contributed Capital
ProceedsFromContributedCapital
|
68000 | ||
us-gaap |
Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
|
25808000 | ||
us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
5051000 | ||
us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
15192000 | ||
us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
315395000 | ||
us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
2260000 | ||
us-gaap |
Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
|
150000 | ||
us-gaap |
Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
|
16607000 | ||
us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
111802000 | ||
pbyi |
Increase Decrease In Prepaid Expense And Other Assets
IncreaseDecreaseInPrepaidExpenseAndOtherAssets
|
7860000 | ||
pbyi |
Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
|
320000 | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
18.84 | ||
us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
|
73.89 | ||
CY2011Q3 | us-gaap |
Noncash Or Part Noncash Acquisition Noncash Financial Or Equity Instrument Consideration Shares Issued1
NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1
|
18666733 | shares |
CY2011Q3 | us-gaap |
Payments For Merger Related Costs
PaymentsForMergerRelatedCosts
|
40000 | |
CY2011Q3 | us-gaap |
Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
|
40000 | |
CY2011Q3 | pbyi |
Noncash Or Part Noncash Acquisition Noncash Financial Or Equity Instrument Shares Received
NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentSharesReceived
|
18666733 | shares |
CY2011 | us-gaap |
Equity Issuance Per Share Amount
EquityIssuancePerShareAmount
|
3.75 | |
CY2011 | us-gaap |
Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
|
61000 | |
CY2011 | us-gaap |
Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
|
7586000 | |
CY2011 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-10233000 | |
CY2011 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
67000 | |
CY2011 | us-gaap |
Other Expenses
OtherExpenses
|
80000 | |
CY2011 | pbyi |
Issuance Of Common Stock In Exchange For Convertible Notes Value
IssuanceOfCommonStockInExchangeForConvertibleNotesValue
|
150000 | |
CY2013 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
11.60 | |
CY2013 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
|
1032375 | shares |
CY2013 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
|
314623 | shares |
CY2013 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
44.77 | |
CY2013 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
19862 | shares |
CY2013 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
7.29 | |
CY2013 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
3000 | |
CY2013 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
2215000 | |
CY2013 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-54659000 | |
CY2013 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
7519000 | |
CY2013 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
23525000 | |
CY2012 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
3.75 | |
CY2012 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
|
1278000 | shares |
CY2012 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
|
11666 | shares |
CY2012 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
11.48 | |
CY2012 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
30000 | shares |
CY2012 | us-gaap |
Equity Issuance Per Share Amount
EquityIssuancePerShareAmount
|
16.00 | |
CY2012 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
3.75 | |
CY2012 | us-gaap |
Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
|
18222000 | |
CY2012 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
45000 | |
CY2012 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-74352000 | |
CY2012 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
1408000 | |
CY2012 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
190000 | |
CY2013Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-18481000 | |
CY2013Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
28676666 | shares |
CY2013Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.41 | |
CY2013Q1 | us-gaap |
Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
|
1000 | |
CY2013Q1 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
-25000 | |
CY2013Q1 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
23000 | |
CY2013Q1 | us-gaap |
Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
|
6723000 | |
CY2013Q1 | us-gaap |
Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
|
27095000 | |
CY2013Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-11780000 | |
CY2013Q1 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
3000 | |
CY2013Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-11805000 | |
CY2013Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-11806000 | |
CY2013Q1 | us-gaap |
Payments For Proceeds From Productive Assets
PaymentsForProceedsFromProductiveAssets
|
183000 | |
CY2013Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
26000 | |
CY2013Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-11780000 | |
CY2013Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
2274000 | |
CY2013Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
1175000 | |
CY2013Q1 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
90000 | |
CY2013Q1 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-45760000 | |
CY2013Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-27279000 | |
CY2013Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
11806000 | |
CY2013Q1 | us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
-6477000 | |
CY2013Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
6405000 | |
CY2013Q1 | us-gaap |
Cost Of Reimbursable Expense
CostOfReimbursableExpense
|
4600000 | |
CY2013Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
9532000 | |
CY2013Q1 | us-gaap |
Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
|
48600 | |
CY2013Q1 | pbyi |
Share Based Compensation Effect On Earnings Per Share Basic And Diluted
ShareBasedCompensationEffectOnEarningsPerShareBasicAndDiluted
|
0.04 | |
CY2013Q1 | pbyi |
Increase Decrease In Prepaid Expense And Other Assets
IncreaseDecreaseInPrepaidExpenseAndOtherAssets
|
1195000 | |
CY2013Q1 | pbyi |
Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
|
24000 | |
CY2014Q1 | dei |
Trading Symbol
TradingSymbol
|
PBYI | |
CY2014Q1 | dei |
Entity Registrant Name
EntityRegistrantName
|
PUMA BIOTECHNOLOGY, INC. | |
CY2014Q1 | dei |
Amendment Flag
AmendmentFlag
|
false | |
CY2014Q1 | dei |
Entity Filer Category
EntityFilerCategory
|
Large Accelerated Filer | |
CY2014Q1 | dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2014 | |
CY2014Q1 | dei |
Document Type
DocumentType
|
10-Q | |
CY2014Q1 | dei |
Document Period End Date
DocumentPeriodEndDate
|
2014-03-31 | |
CY2014Q1 | dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001401667 | |
CY2014Q1 | dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | |
CY2014Q1 | dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q1 | |
CY2014Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
33.95 | |
CY2014Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
|
470625 | shares |
CY2014Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
106.86 | |
CY2014Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-17047000 | |
CY2014Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-17047000 | |
CY2014Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
|
P3Y | |
CY2014Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
29567071 | shares |
CY2014Q1 | us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt"> <b>Concentration of Risk:</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Financial instruments, which potentially subject the Company to concentrations of credit risk, principally consist of cash and cash equivalents. The Company’s cash and cash equivalents in excess of the Federal Deposit Insurance Corporation and the Securities Investor Protection Corporation insured limits at March 31, 2014, were approximately $164.6 million. The Company does not believe it is exposed to any significant credit risk.</p> </div> | |
CY2014Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
15000 | shares |
CY2014Q1 | us-gaap |
Equity Issuance Per Share Amount
EquityIssuancePerShareAmount
|
122.50 | |
CY2014Q1 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Use of Estimates:</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet and reported amounts of expenses for the period presented. Accordingly, actual results could differ from those estimates. Significant estimates include the cost of services provided by consultants who manage clinical trials and conduct research and clinical trials on behalf of the Company that are billed on a delayed basis. As the actual costs become known, the Company adjusts its estimated cost in that period. The value of stock-based compensation includes estimates based on future events, which are difficult to predict. It is at least reasonably possible that a change in the estimates will occur in the near term.</p> </div> | |
CY2014Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.67 | |
CY2014Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
|
P8Y2M12D | |
CY2014Q1 | us-gaap |
Payments For Capital Improvements
PaymentsForCapitalImprovements
|
4000 | |
CY2014Q1 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
-9000 | |
CY2014Q1 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
46000 | |
CY2014Q1 | us-gaap |
Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
|
3483000 | |
CY2014Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-19794000 | |
CY2014Q1 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-21000 | |
CY2014Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-19803000 | |
CY2014Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-19819000 | |
CY2014Q1 | us-gaap |
Payments For Proceeds From Productive Assets
PaymentsForProceedsFromProductiveAssets
|
214000 | |
CY2014Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
25000 | |
CY2014Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-19794000 | |
CY2014Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
5163000 | |
CY2014Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
129440000 | |
CY2014Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
3525000 | |
CY2014Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
5163000 | |
CY2014Q1 | us-gaap |
Depreciation And Amortization
DepreciationAndAmortization
|
133000 | |
CY2014Q1 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
120336000 | |
CY2014Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
7943000 | |
CY2014Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
19819000 | |
CY2014Q1 | us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
-3528000 | |
CY2014Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
4500000 | |
CY2014Q1 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
129440000 | |
CY2014Q1 | us-gaap |
Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
|
8161000 | |
CY2014Q1 | us-gaap |
Cost Of Reimbursable Expense
CostOfReimbursableExpense
|
3500000 | |
CY2014Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
16294000 | |
CY2014Q1 | us-gaap |
Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
|
86800 | |
CY2014Q1 | pbyi |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Remaining Contractual Term
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm
|
P9Y1M6D | |
CY2014Q1 | pbyi |
Share Based Compensation Effect On Earnings Per Share Basic And Diluted
ShareBasedCompensationEffectOnEarningsPerShareBasicAndDiluted
|
0.17 | |
CY2014Q1 | pbyi |
Increase Decrease In Prepaid Expense And Other Assets
IncreaseDecreaseInPrepaidExpenseAndOtherAssets
|
145000 | |
CY2014Q1 | pbyi |
Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
|
107000 | |
CY2014Q1 | pbyi |
License Agreement Number Of Days To Review Invoice And Supporting Documentation
LicenseAgreementNumberOfDaysToReviewInvoiceAndSupportingDocumentation
|
P60D |